Literature DB >> 20056614

Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies.

Leo Borras1, Tea Gunde, Julia Tietz, Ulrich Bauer, Valérie Hulmann-Cottier, John P A Grimshaw, David M Urech.   

Abstract

Despite their favorable pharmacokinetic properties, single-chain Fv antibody fragments (scFvs) are not commonly used as therapeutics, mainly due to generally low stabilities and poor production yields. In this work, we describe the identification and optimization of a human scFv scaffold, termed FW1.4, which is suitable for humanization and stabilization of a broad variety of rabbit antibody variable domains. A motif consisting of five structurally relevant framework residues that are highly conserved in rabbit variable domains was introduced into FW1.4 to generate a generically applicable scFv scaffold, termed FW1.4gen. Grafting of complementarity determining regions (CDRs) from 15 different rabbit monoclonal antibodies onto FW1.4 and their derivatives resulted in humanized scFvs with binding affinities in the range from 4.7 x 10(-9) to 1.5 x 10(-11) m. Interestingly, minimalistic grafting of CDRs onto FW1.4gen, without any substitutions in the framework regions, resulted in affinities ranging from 5.7 x 10(-10) to <1.8 x 10(-12) m. When compared with progenitor rabbit scFvs, affinities of most humanized scFvs were similar. Moreover, in contrast to progenitor scFvs, which were difficult to produce, biophysical properties of the humanized scFvs were significantly improved, as exemplified by generally good production yields in a generic refolding process and by apparent melting temperatures between 53 and 86 degrees C. Thus, minimalistic grafting of rabbit CDRs on the FW1.4gen scaffold presents a simple and reproducible approach to humanize and stabilize rabbit variable domains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056614      PMCID: PMC2838326          DOI: 10.1074/jbc.M109.072876

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.

Authors:  Stefan Ewert; Annemarie Honegger; Andreas Plückthun
Journal:  Biochemistry       Date:  2003-02-18       Impact factor: 3.162

2.  Consensus-based engineering of protein stability: from intrabodies to thermostable enzymes.

Authors:  Boris Steipe
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

3.  Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.

Authors:  Sachdev S Sidhu; Bing Li; Yvonne Chen; Frederic A Fellouse; Charles Eigenbrot; Germaine Fuh
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

4.  Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.

Authors:  Germaine Fuh; Ping Wu; Wei-Ching Liang; Mark Ultsch; Chingwei V Lee; Barbara Moffat; Christian Wiesmann
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

Review 5.  Protein engineering techniques for antibody humanization.

Authors:  M R Hurle; M Gross
Journal:  Curr Opin Biotechnol       Date:  1994-08       Impact factor: 9.740

6.  Humanization of the murine anti-human CD3 monoclonal antibody OKT3.

Authors:  J R Adair; D S Athwal; M W Bodmer; S M Bright; A M Collins; V L Pulito; P E Rao; R Reedman; A L Rothermel; D Xu
Journal:  Hum Antibodies Hybridomas       Date:  1994

Review 7.  Engineering antibodies for therapy.

Authors:  A Mountain; J R Adair
Journal:  Biotechnol Genet Eng Rev       Date:  1992

8.  Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.

Authors:  Frederic A Fellouse; Christian Wiesmann; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

9.  Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.

Authors:  Michael Ottiger; Michael A Thiel; Ulrich Feige; Peter Lichtlen; David M Urech
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799

10.  Tailoring in vitro evolution for protein affinity or stability.

Authors:  L Jermutus; A Honegger; F Schwesinger; J Hanes; A Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  17 in total

1.  High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system.

Authors:  Yafang Tan; Tiantian Tang; Haisheng Xu; Chenqi Zhu; Brian T Cunningham
Journal:  Biosens Bioelectron       Date:  2015-05-19       Impact factor: 10.618

2.  Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Authors:  Haiyong Peng; Thomas Nerreter; Jing Chang; Junpeng Qi; Xiuling Li; Pabalu Karunadharma; Gustavo J Martinez; Mohammad Fallahi; Jo Soden; Jim Freeth; Roger R Beerli; Ulf Grawunder; Michael Hudecek; Christoph Rader
Journal:  J Mol Biol       Date:  2017-08-14       Impact factor: 5.469

3.  Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein.

Authors:  Dabin Liu; Chen Wang; Cun Li; Xin Zhang; Baozhong Zhang; Zhiqiang Mi; Xiaoping An; Yigang Tong
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

4.  Thermodynamic stability and flexibility characteristics of antibody fragment complexes.

Authors:  Tong Li; Deeptak Verma; Malgorzata B Tracka; Jose Casas-Finet; Dennis R Livesay; Donald J Jacobs
Journal:  Protein Pept Lett       Date:  2014       Impact factor: 1.890

5.  Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples.

Authors:  Yi-Fan Zhang; Mitchell Ho
Journal:  MAbs       Date:  2017-02-06       Impact factor: 5.857

6.  Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Authors:  Jared L Spidel; Earl F Albone; Xin Cheng; Benjamin Vaessen; Sara Jacob; Andrew Z Milinichik; Arielle Verdi; J Bradford Kline; Luigi Grasso
Journal:  MAbs       Date:  2017-05-25       Impact factor: 5.857

7.  Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

Authors:  Jiahui Yang; Sivasubramanian Baskar; Ka Yin Kwong; Michael G Kennedy; Adrian Wiestner; Christoph Rader
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

8.  Co-crystallization with diabodies: A case study for the introduction of synthetic symmetry.

Authors:  Chelsy Chesterman; Eddy Arnold
Journal:  Structure       Date:  2021-02-25       Impact factor: 5.871

Review 9.  From rabbit antibody repertoires to rabbit monoclonal antibodies.

Authors:  Justus Weber; Haiyong Peng; Christoph Rader
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

10.  Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities.

Authors:  Naoya Shinozaki; Ryuji Hashimoto; Kiichi Fukui; Susumu Uchiyama
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.